TMSL's Holdings Imply 14% Gain Potential

The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $39.61, representing a 13.86% upside from its current $34.79, based on the weighted average of its underlying holdings' analyst targets. Key contributors to this projected growth include Celldex Therapeutics (CLDX) with a 146.42% potential upside, Avidity Biosciences (RNA) at 40.11%, and Service Corp. International (SCI) at 15.10%. This analysis highlights specific high-conviction opportunities within the ETF's portfolio, though the article suggests these targets warrant further investor research into their justification.

Analysis

An analysis of the T. Rowe Price Small - Mid Cap ETF (TMSL) reveals a significant potential upside of 13.86%, based on a weighted average of analyst 12-month forward price targets for its underlying holdings. The ETF's implied target price is calculated at $39.61 per unit, compared to its recent trading price of $34.79. This projected growth is heavily influenced by a few specific holdings with exceptionally optimistic analyst outlooks. Notably, Celldex Therapeutics (CLDX) has an average analyst target 146.42% above its recent price, while Avidity Biosciences (RNA) and Service Corp. International (SCI) show potential upsides of 40.11% and 15.10%, respectively. While these figures suggest strong conviction from analysts, particularly in the biotechnology sector, the analysis is framed with a note of caution, questioning whether these targets are justified or could be precursors to future downgrades. The data therefore presents a dichotomy: a quantitatively attractive opportunity based on consensus estimates, tempered by the qualitative risk that these forecasts may be overly optimistic and require further independent validation.

Key Decisions for Investors

• Investors should perform focused due diligence on the ETF's key underlying holdings, particularly Celldex Therapeutics (CLDX) and Avidity Biosciences (RNA), to validate the fundamental catalysts supporting the highly optimistic analyst targets.
• The 13.86% implied upside should be viewed as a starting point for research, not a guaranteed return, warranting a cautious approach that weighs potential rewards against the risk of sell-side optimism not materializing.